Elayta Shows Potential for Improving Brain Cell Activity in Alzheimer’s, Trial Results Show

Elayta Shows Potential for Improving Brain Cell Activity in Alzheimer’s, Trial Results Show
Cognition Therapeutics’ lead investigative therapy Elayta (CT1812) shows promise in improving the activity of brain cells in patients with Alzheimer’s disease, according to the results of a Phase 1b/2a trial. Elayta is a small molecule that displaces amyloid-beta oligomers formed in Alzheimer’s disease from their binding sites, or receptors, on nerve cells in the brain. Preclinical

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *